Insights
Search Results
Client Highlights
6.02.26
Firm Advises Noctrix on Acquisition by Resmed
On June 1, 2026, Resmed, a medical device company that develops, manufactures, and distributes medical equipment for the diagnosis, treatment, and management of respiratory disorders, announced it has closed on its acquisition of Noctrix Health, a medical device company that developed and manufactures a novel therapy to treat drug-refractory Restless Legs Syndrome (RLS) for $340 million. Wilson Sonsini Goodrich & Rosati advised Noctrix on the transaction.
Client Highlights
11.18.25
Firm Advises ABL Bio on Strategic Alliance and Equity Investment with Eli Lilly
On November 14, 2025, ABL Bio announced a broad strategic research and development alliance with Eli Lilly and Company, establishing a multi-program collaboration to advance next-generation therapeutics using ABL Bio’s Grabody Platform. Wilson Sonsini Goodrich & Rosati advised ABL Bio on the license, research, and collaboration agreement, which is valued at up to $2.602 billion, including a $40 million upfront payment. Through this partnership, ABL Bio and Lilly will jointly explore and develop multiple therapeutic modalities across a range of disease areas, marking a significant expansion of ABL Bio’s platform-driven global collaborations.
Client Highlights
1.22.25
Wilson Sonsini Advises Divvy Homes on Sale of Portfolio and Platform to Brookfield
On January 22, 2025, Divvy Homes, a market leader in the proptech industry, announced that they have entered into a definitive agreement whereby a Brookfield private real estate fund will acquire Divvy Homes’ property portfolio and platform for a total consideration of approximately $1 billion. Maymont Homes, Brookfield’s single-family home rental business, will manage the portfolio on an ongoing basis. Wilson Sonsini Goodrich & Rosati advised Divvy Homes on the transaction.
Client Highlights
1.13.25
Wilson Sonsini Advises Bolt Medical on Merger with Boston Scientific
On January 8, 2025, Boston Scientific announced it has entered into a definitive agreement to acquire Bolt Medical, the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for the treatment of coronary and peripheral artery disease, for up to $900 million. Wilson Sonsini Goodrich & Rosati advised Bolt Medical on the transaction.
Client Highlights
3.15.22
Wilson Sonsini Advises Nalu Medical on $104 Million Equity Financing
On February 17, 2022, Nalu Medical, Inc., a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced a $104 million equity financing. The round was led by new investors MVM Partners and Gilde Healthcare. New investors Pura Vida Investments and Aperture Venture Partners, as well as existing investors Advent Life Sciences, Decheng Capital, Endeavour Vision, and Longitude Capital, also participated in the round. The proceeds from this financing are intended to be used for scaling commercial operations to accelerate growth, continued expansion of clinical evidence, and continuing product development, in addition to other general corporate purposes. Wilson Sonsini Goodrich & Rosati advised Nalu Medical on the transaction.
Client Highlights
8.18.21
Wilson Sonsini Advises Divvy Homes on $200 Million Series D
On August 13, 2021, Divvy Homes announced the completion of a $200 million Series D financing that further extends their position as a market leader in the proptech industry. Divvy Homes' accelerating growth caught the attention of its lead investors, who preempted the Series D and valued Divvy Homes at approximately $2 billion. Wilson Sonsini Goodrich & Rosati represented Divvy Homes in the transaction.
Client Highlights
4.29.21
Wilson Sonsini Advises Ceribell on $53 Million Series C Financing
On April 29, 2021, Ceribell, innovator of the Rapid Response EEG™, a novel non-invasive brain monitor, announced the completion of a $53 million Series C financing, which was co-led by Longitude Capital and The Rise Fund. Other new investors include RA Capital Management, Redmile Group, and Red Tree Venture Capital, with additional support from existing shareholders. Wilson Sonsini Goodrich & Rosati represented Ceribell in the transaction.
Client Highlights
5.11.20
CorVent Medical, a Coridea Company, Raises $4.5 Million to Commercialize First Single-Use, Critical Care Ventilator
On May 11, 2020, CorVent Medical, a Coridea portfolio company, announced the closing of a $4.5 million seed financing round to support the commercialization of the first single-use, critical care ventilator that will enable rapid and affordable deployment with superior infection control. The financing round is led by the prominent European life sciences venture capital firm Sofinnova Partners with participation from Redmile Group, Exor Seeds, Genesis Medtech Group, The Deerfield Foundation, The Pagliuca Family Office, and Accel Founder Jim Swartz. Funds will be used to finalize regulatory filings under the U.S. Food and Drug Administration's Emergency Use Authorization (EUA) Act, to upon approval launch the CorVent™ Single-Use Ventilator, and to support future development of next generation lifesaving devices for respiratory insufficiency. Wilson Sonsini Goodrich & Rosati represented CorVent Medical in the transaction.
Client Highlights
4.10.19
Silk Road Medical Announces Closing of IPO
On April 8, 2019, Sunnyvale, California-based Silk Road Medical, a medical device company focused on reducing strokes through minimally invasive technology that safely and effectively treats carotid artery disease through "transcarotid artery revascularization," announced the closing of its initial public offering of 6,000,000 shares of common stock, and the full exercise of the underwriters' option to purchase 900,000 additional shares of common stock from the selling stockholders, at a public offering price of $20.00 per share.
Client Highlights
9.18.18
IRIDEX Closes Follow-On Offering
On September 18, 2018, IRIDEX, an ophthalmology company focused on the development and commercialization of novel products and procedures used to treat glaucoma and retinal diseases, closed its underwritten public offering of 1,666,667 shares of its common stock at a price to the public of $6.00 per share. In addition, the company granted the underwriters a 30-day option to purchase up to 250,000 additional shares of its common stock in the public offering and the option was exercised prior to closing. Wilson Sonsini Goodrich & Rosati represented IRIDEX in the offering.